$5.63
6.32% day before yesterday
Nasdaq, Oct 03, 10:04 pm CET
ISIN
US83548R1059
Symbol
SONN

Sonnet BioTherapeutics Holdings Inc Stock price

$5.63
+2.50 79.87% 1M
+4.36 343.31% 6M
+4.17 285.62% YTD
+0.48 9.21% 1Y
-254.85 97.84% 3Y
-6,770.37 99.92% 5Y
-788,045.63 100.00% 10Y
+4.63 463.00% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.38 6.32%
ISIN
US83548R1059
Symbol
SONN
Industry

Key metrics

Basic
Market capitalization
$38.4m
Enterprise Value
$38.1m
Net debt
positive
Cash
$320.0k
Shares outstanding
3.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
38.4 | 37.7
EV/Sales
38.1 | 37.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-17.5%
Return on Equity
1,531.2%
ROCE
439.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.0m | $1.0m
EBITDA
$-13.2m | $-46.2m
EBIT
$-13.4m | $14.8m
Net Income
$-13.6m | $-11.8m
Free Cash Flow
$-10.3m
Growth (TTM | estimate)
Revenue
1,566.7% | 5,000.0%
EBITDA
-7.8% | -292.6%
EBIT
-8.8% | 224.9%
Net Income
-69.7% | -57.9%
Free Cash Flow
-1.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,321.9% | -4,530.0%
EBIT
-1,335.9%
Net
-1,355.6% | -1,152.2%
Free Cash Flow
-1,032.3%
More
EPS
$-3.4
FCF per Share
$-3.1
Short interest
32.8%
Employees
13
Rev per Employee
$0.0
Show more

Is Sonnet BioTherapeutics Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Sonnet BioTherapeutics Holdings Inc forecast:

Buy
86%
Hold
14%

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1 1
1,567% 1,567%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.66 7.66
29% 29%
766%
- Research and Development Expense 7.40 7.40
16% 16%
740%
-13 -13
8% 8%
-1,322%
- Depreciation and Amortization 0.14 0.14
1,300% 1,300%
14%
EBIT (Operating Income) EBIT -13 -13
9% 9%
-1,336%
Net Profit -14 -14
70% 70%
-1,356%

In millions USD.

Don't miss a Thing! We will send you all news about Sonnet BioTherapeutics Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral
GlobeNewsWire
16 days ago
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech...
Neutral
GlobeNewsWire
about 2 months ago
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Neutral
GlobeNewsWire
2 months ago
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)
More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office United States
CEO Raghu Rao
Employees 13
Founded 2011
Website www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today